On 9 February 2026 USTR Ambassador Jamieson Greer and Bangladesh Adviser Sheikh Bashir Uddin signed the Agreement on Reciprocal Trade (ART) between the United States and Bangladesh in Washington DC — USTR's first ART signing in South Asia, preceding the US-India interim-trade-framework finalisation by three days. The deal locks the US reciprocal tariff on Bangladesh-originating goods at 19% (down from 35% under the April 2025 IEEPA regime) and establishes a zero-percent mechanism for products on the Annex III aligned- partner list (EO 14346, 5 September 2025). Bangladesh commits to significant preferential market access for US industrial and agricultural goods — including chemicals, machinery, motor vehicles, medical devices, ICT equipment, energy products, soy, dairy, beef, poultry, tree nuts, and fruit — and to eliminating specified non- tariff barriers including acceptance of US Federal motor-vehicle safety and emissions standards, FDA certificates, and prior marketing authorisations for medical devices and pharmaceuticals.

Analyst notesShow

Mechanism

The ART is layered on top of the April 2025 IEEPA-grounded US reciprocal-tariff architecture. It does not dismantle the IEEPA tariff authority; it fixes Bangladesh's country rate at 19% and adds reciprocal Bangladeshi market-access commitments. Three structural levers:

1. Tariff cap on Bangladesh exports to US (19%), down from the 35% IEEPA rate. Selected products on the Annex III aligned-partner list (EO 14346, 5 September 2025) receive a 0% reciprocal tariff rate. This is of direct relevance to Bangladesh's ~USD 56bn/yr ready-made garment (RMG) export base — the sector employs roughly 7 million workers and accounts for ~84% of Bangladesh total export earnings.

2. Bangladesh preferential market access for US goods across chemicals, medical devices, machinery and motor-vehicle parts, ICT equipment, energy products, soy products, dairy, beef, poultry, tree nuts, and fruit. The commitment structure mirrors prior US ARTs but is notably lighter on natural-resource / critical-minerals clauses (compare US-Indonesia ART's export-restriction rollback) reflecting Bangladesh's trade profile as an apparel exporter rather than a resource-extraction economy.

3. Non-tariff barrier (NTB) elimination, including: - Acceptance of vehicles built to US Federal motor-vehicle safety and emissions standards (opens potential automotive-export channel for US OEMs). - Acceptance of FDA certificates and prior marketing authorisations for US medical devices and pharmaceuticals (reduces dual-approval burden for US MedTech exporters into Bangladesh's 175m-person market). - Removal of any import restrictions or licensing requirements on US goods.

Severity 3 (mixed). The 19% rate is tariff-relieving vs. the 35% IEEPA baseline, which is protective for Bangladesh's RMG export base. The LDC-graduation context (Bangladesh exits LDC status 24 November 2026, triggering EU EBA preference-loss) makes securing a US tariff cap structurally significant: it partially offsets the imminent loss of zero-duty EU access for ~35% of current RMG export revenue.

LDC-graduation context

Bangladesh is scheduled to graduate from Least Developed Country (LDC) status on 24 November 2026, triggering the loss of EU Everything But Arms (EBA) zero-duty / zero-quota preferences on its garment exports to the EU (~USD 20bn+/yr). The US ART's 19% cap (vs. the 35% IEEPA baseline) locks in a preferential US market-access architecture at exactly the moment Bangladesh faces its single largest trade-policy cliff since independence. The agreement thus functions partially as a US diplomatic offset to the EU EBA-loss — a structurally significant timing coincidence (or deliberate sequencing) that anchors Bangladesh's post-LDC export trajectory.

Downstream implications

Bangladesh RMG sector: 19% US tariff cap vs. 35% IEEPA baseline

is meaningfully positive for Bangladesh's garment manufacturers and for buyers (H&M, Zara/Inditex, PVH, Gap) with concentrated Bangladeshi sourcing exposure. Zero-tariff basket (Annex III) adds upside for aligned-product categories.

US agricultural exporters: Bangladesh's preferential market-

access commitments open structured channels for US soy, dairy, beef, poultry and tree-nut/fruit exports into a 175m-person market that is currently dominated by Indian + Australian agricultural suppliers.

US MedTech / pharma: FDA-certificate acceptance removes the

dual-approval barrier that has historically constrained US MedTech market share in South Asian emerging markets.

Precedent for South Asia ART sequence: USTR explicitly described

this as the "first in South Asia" — coming 3 days before the US-India ART (2026-02-06) was finalised and 10 days before the US-Indonesia ART (2026-02-19). The sequence suggests a coordinated push to pre-empt China's bilateral-trade deepening in the ASEAN/South Asia corridor following the April 2025 IEEPA shock.